Cross-reactivity between Candida albicans and ovarian cancer
Author Information
Author(s): J Schneider, D Moragues, N Martinez, H Romero, E Jimenez, J Pontón
Primary Institution: Universidad del País Vasco
Hypothesis
Can antibodies against Candida albicans cross-react with human ovarian carcinoma?
Conclusion
The study found that a significant number of aggressive ovarian carcinomas expressed an antigen recognized by the monoclonal antibody PA1OF, suggesting a link between Candida albicans and ovarian cancer aggressiveness.
Supporting Evidence
- 67.6% of the ovarian carcinomas tested expressed the antigen recognized by PA1OF.
- 19 out of 24 aggressive, advanced-stage tumours were positive for the antigen.
- Only 2 out of 13 borderline carcinomas expressed the antigen.
Takeaway
Researchers found that some antibodies made to fight a yeast called Candida albicans can also recognize and react with certain ovarian cancer cells.
Methodology
The study used immunohistochemistry to test 37 human ovarian carcinoma samples for the presence of antigens recognized by monoclonal antibodies PA1OF and C6.
Limitations
The study primarily focused on a small sample size and may not represent all ovarian cancer types.
Participant Demographics
The study involved human ovarian carcinoma samples, but specific demographic details were not provided.
Statistical Information
P-Value
0.0007
Statistical Significance
p=0.0007
Want to read the original?
Access the complete publication on the publisher's website